Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Praxis Precision Medicines
Biotech
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Former Roche oncology head turns to Tubulis. Argenx CEO passes baton to operating chief. Longtime Charles River leader eyes retirement.
Darren Incorvaia
,
Zoey Becker
Jan 9, 2026 8:30am
Praxis sees success in ph. 2 seizure trial, setting up FDA push
Dec 5, 2025 10:00am
Praxis plots path to FDA after phase 3 wins in essential tremor
Oct 16, 2025 11:48am
Praxis' drug reduces seizures but sees 23% discontinuation rate
Aug 4, 2025 10:22am
Praxis moves ahead despite phase 3 tremor trial futility finding
Feb 28, 2025 9:11am
Praxis epilepsy drug reduces seizures in phase 2 trial
Sep 3, 2024 10:21am